Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity